SHANDONG XINHUA (00719) announced its interim results for 2025, reporting revenue of approximately RMB 4.639 billion, representing a year-on-year decrease of 1.98%. Net profit attributable to shareholders reached approximately RMB 224 million, down 15.69% compared to the same period last year. Basic earnings per share stood at RMB 0.32. During the first half of the year, 10 new pharmaceutical products were launched to the market.

As of the end of the reporting period, a cumulative total of 19 products across 25 specifications successfully won bids in national centralized procurement. The pharmaceutical processing and export business maintained steady growth, with self-operated pharmaceutical exports achieving significant development.

Leveraging the competitive advantages of key raw material drug production and focusing intensively on cost reduction, the company achieved increased production of 11 key raw material drugs including ibuprofen and aspirin. Market share expanded and the global market position was further consolidated. Sales volume of specialty raw material drugs achieved rapid growth.

In the first half of the year, the company obtained 21 drug approvals, including 19 new pharmaceutical products such as pentazocine injection and empagliflozin tablets, as well as 2 raw material drug approvals for icosapent ethyl and sacubitril valsartan sodium. The company also received 3 consistency evaluation approvals including tramadol hydrochloride sustained-release tablets, with 1 being the first nationwide and 1 being the second nationwide to pass evaluation.

The company initiated Phase II clinical work for OAB-14, a Class 1 innovative drug for treating Alzheimer's disease. During the first half, 18 patents were authorized, including 8 invention patents. One project received the second prize of Shandong Province Science and Technology Progress Award for 2024, and one project was listed as a provincial major science and technology innovation engineering project for 2025.